Skip to main content

Table 2 Estimation of average treatment effects and potential outcome mean of RAAS blockade on ESRD by diabetic groups

From: Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients

Model for diabetic patients

Treatments

RD

LL.

UL

NNT

LL

UL

 ATE

RAAS1 vs non-RAAS

−0.0100

−0.0445

0.0246

−100.3

−447.6

247.0

 

RAAS2 vs non-RAAS

−0.0712

−0.0878

−0.0547

−14.0

−17.3

−10.8

  

Risk

LL

UL

RR

LL

UL

 POM

Non-RAAS

0.1999

0.1917

0.2082

1

  
 

RAAS1

0.1899

0.0779

0.1905

0.950

0.778

1.123

 

RAAS2

0.1287

0.1139

0.1435

0.644

0.567

0.721

Model for non-diabetic patients

Treatments

RD

LL.

UL

NNT

LL

UL

 ATE

RAAS1 vs non-RAAS

−0.0205

0–.0863

0.0453

−48.7

−204.9

107.5

 

RAAS2 vs non-RAAS

−0.0674

−0.1216

−0.0132

−14.8

−26. 8

−2.9

  

Risk

LL

UL

RR

LL

UL

 POM

Non-RAAS

0.1812

0.1745

0.1879

1

  
 

RAAS1

0.1607

0.0949

0.2265

0.887

0.523

1.250

 

RAAS2

0.1139

0.0598

0.1679

0.628

0.3301

0.926

  1. ATE Average treatment effect, LL Lower limit, POM Potential outcome mean, RAAS1 Duration use of 0.25–1 year, RAAS2 Duration use of >1 year, RD Risk difference, RR Rate ratio, UL Upper limit